Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for improving overall survival of patients with plasma cell leukemia. Consolidation therapy is treatment given after initial therapy to kill any cancer cells that may remain in the body. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Carfilzomib inhibits protein complexes called proteasomes, which inhibits cancer cell growth and leads to cancer cell death. Lenalidomide may help kill cancer cells and prevents the growth of blood vessels that cancer cells need to survive. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Teclistamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving teclistamab as consolidation therapy after induction and autologous hematopoietic stem cell transplant may improve survival outcomes in patients with plasma cell leukemia, compared to standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza pierwotnej białaczki plazmocytowej
- •Mierzalne objawy choroby w badaniach krwi lub moczu
- •Wiek 18-80 lat
- •Maksymalnie jeden cykl leczenia przygotowującego wcześniej
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
✗ Disqualifies
- •Ciąża lub karmienie piersią
- •Ciężka alergia na lenalidomid lub podobne leki immunomodulujące
- •Poważne problemy z sercem lub płucami z powodu wcześniejszej chemioterapii
- •Kobiety w wieku rozrodczym muszą stosować skuteczną antykoncepcję
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- October 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Yale University
New Haven, United States
Yale-New Haven Hospital North Haven Medical Center
North Haven, United States
Our Lady of the Lake Physician Group
Baton Rouge, United States
Memorial Sloan Kettering Monmouth
Middletown, United States
Memorial Sloan Kettering Bergen
Montvale, United States
Roswell Park Cancer Institute
Buffalo, United States
Memorial Sloan Kettering Commack
Commack, United States
Memorial Sloan Kettering Westchester
Harrison, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, United States
Trial contact
Site Public Contact
Terri L. Parker
PRINCIPAL_INVESTIGATOR
Site Public Contact
Hana F. Safah
PRINCIPAL_INVESTIGATOR
Site Public Contact
Hani Hassoun
PRINCIPAL_INVESTIGATOR
Site Public Contact
Hamza Hassan
PRINCIPAL_INVESTIGATOR
Site Public Contact
Douglas W. Sborov
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.